Texas is currently home to 4852 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
NCT06096025
Recruiting
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/15/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Streptococcus Pneumoniae
Register for Updates
Penetrating Trauma Registry and Open Source Data
NCT06136273
Recruiting
Penetrating injuries comprise roughly 30% of Methodist Health System (MHS) trauma patients. Firearm-related events have become more prevalent in the past few years. Active shooter events, mass casualties, assaults, and homicide are more commonplace which leads to an increase of trauma patients needing management of penetrating injuries.
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
11/14/2023
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Penetrating Trauma Registry and Open Source Data
Register for Updates
Clinical Outcome of Pericardial Closure Using Gentrix Following Cardiac Surgery
NCT06136182
Recruiting
A descriptive comparative project will be conducted to determine if there is a difference in outcomes for adult patients requiring pericardial reconstruction using CorMatrix compared to Gentrix
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/14/2023
Locations: Clinical Research Institute at Methodist Health System, Dallas, Texas
Conditions: Clinical Outcome of Pericardial Closure Using Gentrix
Register for Updates
DETEC® Esterase for Screening Wound Infection at Point of Care
NCT04614870
Recruiting
This non-interventional, single-blinded, prospective, observational study assesses the planar distribution of leukocyte esterase in wounds by placing wound exudates soaked wound dressings in the DETEC® Esterase device during routine wound care. The output of the device is correlated with clinical determination of infection to assess the device efficacy in identifying presumptive infections.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/14/2023
Locations: Complex Healthcare Solutions, Arlington, Texas
Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
Register for Updates
DETEC® pH Point of Care Wound Diagnostic Test
NCT04614038
Recruiting
The purpose of this study is to determine the relationship between wound alkalinity and the non-healing status of chronic ulcer wounds. It is hypothesized that wounds with an alkaline environment as indicated by DETEC pH will have a high chance of not healing over 12 weeks of wound care.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/14/2023
Locations: Complex Healthcare Solutions, Arlington, Texas
Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer, Wound, Non-Healed
Register for Updates
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
NCT04870853
Recruiting
This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory). The results from this study may allow a description of these events, their managements and outcome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates
Treatment of PAF With the Synaptic System
NCT05905835
Recruiting
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/09/2023
Locations: Christus Health Frances Hospital, Tyler, Texas
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON Early Phase Services, LLC, San Antonio, Texas
Conditions: Rheumatoid Arthritis
Register for Updates
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT04016389
Recruiting
This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy dru... Read More
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
11/03/2023
Locations: MD Anderson Cancer Centre, Houston, Texas
Conditions: Cervical Cancer
Register for Updates
Project Sueño: Sleep & Understanding Early Nutrition in Obesity
NCT06117631
Recruiting
The purpose of the study is to understand how mothers think and feel about feeding their babies and putting them to sleep, understand more about programs that can support mothers taking care of babies, and how professionals can be most helpful in helping mothers make decisions about their baby's feeding and sleeping. The overarching goal is to prevent early life obesity and progression to metabolic syndrome in high-risk populations, starting with healthy toddler weights by age 2 years.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
11/01/2023
Locations: CommUnity Care: North Central Health Center, Austin, Texas
Conditions: Infant Overweight, Infant Obesity, Infant Overnutrition, Infant Development, Metabolic Syndrome, Diabetes Mellitus Risk
Register for Updates
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
NCT04321954
Recruiting
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Differentiated Thyroid Cancer, Advanced Cancer
Register for Updates
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT05094804
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: NEXT Austin, Austin, Texas
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Register for Updates